Patents by Inventor Amer M. Mirza

Amer M. Mirza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CANCER USING INHIBITORS OF TGF-BETA AND PD-1
    Publication number: 20230416354
    Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
    Type: Application
    Filed: May 11, 2023
    Publication date: December 28, 2023
    Inventors: Amer M Mirza, Rosemary J. Akhurst, Ou Li
  • Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
    Patent number: 11787876
    Abstract: The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: October 17, 2023
    Assignee: XOMA (US) LLC
    Inventors: Raphael D. Levy, Hassan Issafras, Agnes Choppin Holmes, Kirk W. Johnson, Amer M. Mirza, Daniel H. Bedinger, Rachel A. Hunt, Toshihiko Takeuchi, Kiranjit Kaur Ahluwalia, Robyn Cotter
  • Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by administering to a subject a TGF-beta inhibitor and a PD-1 antibody
    Patent number: 11685775
    Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: June 27, 2023
    Assignees: XOMA TECHNOLOGY LTD., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Amer M. Mirza, Rosemary J. Akhurst, Ou Li
  • Antibodies Specific for TGF-Beta
    Publication number: 20210355204
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Application
    Filed: July 15, 2021
    Publication date: November 18, 2021
    Inventors: Daniel H. Bedinger, Shireen S. Khan, Amer M. Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • ANTIBODIES THAT BIND INTERLEUKIN-2 AND USES THEREOF
    Publication number: 20210188969
    Abstract: The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.
    Type: Application
    Filed: December 4, 2020
    Publication date: June 24, 2021
    Inventors: Marina Roell, Mark Rubinstein, Hassan Issafras, Llewelyn Lao, Ou Li, Daniel H. Bedinger, Kristin Camfield Lind, Agnes Choppin Holmes, Toshihiko Takeuchi, Lauren Schwimmer, Hoa Giang, Amer M. Mirza, Kirk W. Johnson
  • Antibodies that bind interleukin-2 and uses thereof
    Patent number: 10858428
    Abstract: The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: December 8, 2020
    Assignees: XOMA (US) LLC, MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Marina Roell, Mark Rubinstein, Hassan Issafras, Llewelyn Lao, Ou Li, Daniel H. Bedinger, Kristin Camfield Lind, Agnes Choppin Holmes, Toshihiko Takeuchi, Lauren Schwimmer, Hoa Giang, Amer M. Mirza, Kirk W. Johnson
  • Parathyroid Hormone Receptor 1 (PTH1R) Antibodies and Uses Thereof
    Publication number: 20200317817
    Abstract: The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.
    Type: Application
    Filed: November 26, 2019
    Publication date: October 8, 2020
    Inventors: Raphael D. Levy, Hassan Issafras, Agnes Choppin Holmes, Kirk W. Johnson, Amer M. Mirza, Daniel H. Bedinger, Rachel A. Hunt, Toshikiko Takeuchi, Kiranjit Kaur Ahluwalia, Robyn Cotter
  • Treatment of Cancer Using Inhibitors of TGF-Beta and PD-1
    Publication number: 20200308266
    Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
    Type: Application
    Filed: June 15, 2020
    Publication date: October 1, 2020
    Inventors: Amer M. Mirza, Rosemary J. Akhurst, Ou Li
  • Treatment of cancer using anti-TGF-? and anti-PD-1 antibodies
    Patent number: 10683347
    Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: June 16, 2020
    Assignees: XOMA Technology Ltd., The Regents of the University of California
    Inventors: Amer M. Mirza, Rosemary J. Akhurst, Ou Li
  • Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
    Patent number: 10519250
    Abstract: The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: December 31, 2019
    Assignee: XOMA (US) LLC
    Inventors: Raphael D. Levy, Hassan Issafras, Agnes Choppin Holmes, Kirk W. Johnson, Amer M. Mirza, Daniel H. Bedinger, Rachel A. Hunt, Toshihiko Takeuchi, Kiranjit Kaur Ahluwalia, Robyn Cotter
  • Treatment of Cancer Using Inhibitors of TGF-Beta and PD-1
    Publication number: 20190112366
    Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
    Type: Application
    Filed: December 17, 2018
    Publication date: April 18, 2019
    Inventors: Amer M. Mirza, Rosemary J. Akhurst, Ou Li
  • Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
    Patent number: 10167334
    Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
    Type: Grant
    Filed: April 3, 2016
    Date of Patent: January 1, 2019
    Assignees: XOMA TECHNOLOGY LTD., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Amer M. Mirza, Rosemary J. Akhurst, Ou Li
  • Antibodies That Bind Interleukin-2 and Uses Thereof
    Publication number: 20180094053
    Abstract: The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.
    Type: Application
    Filed: September 28, 2017
    Publication date: April 5, 2018
    Inventors: Marina Roell, Mark Rubinstein, Hassan Issafras, Llewelyn Lao, Ou Li, Daniel H. Bedinger, Kristin Camfield Lind, Agnes Choppin Holmes, Toshihiko Takeuchi, Lauren Schwimmer, Hoa Giang, Amer M. Mirza, Kirk W. Johnson
  • Parathyroid Hormone Receptor 1 (PTH1R) Antibodies and Uses Thereof
    Publication number: 20180030154
    Abstract: The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.
    Type: Application
    Filed: August 1, 2017
    Publication date: February 1, 2018
    Inventors: Raphael D. Levy, Hassan Issafras, Agnes Choppin Holmes, Kirk W. Johnson, Amer M. Mirza, Daniel H. Bedinger, Rachel A. Hunt, Toshihiko Takeuchi, Kiranjit Kaur Ahluwalia, Robyn Cotter
  • Treatment of Cancer Using Inhibitors of TGF-BETA and PD-1
    Publication number: 20160289315
    Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
    Type: Application
    Filed: April 3, 2016
    Publication date: October 6, 2016
    Inventors: Amer M. Mirza, Rosemary J. Akhurst, Ou Li
  • USES OF ANTI-CD40 ANTIBODIES
    Publication number: 20110002934
    Abstract: This invention relates to new uses of anti-CD40 antibodies in the treatment of diseases or conditions associated with neoplastic B-cell growth in particular use of anti-CD40 antibodies in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). The invention is particularly useful for the treatment of patients who have previously been administered (i) CHOP, (ii) the chimeric anti-CD20 monoclonal antibody rituximab, or (iii) combination therapy with CHOP and rituximab.
    Type: Application
    Filed: November 7, 2008
    Publication date: January 6, 2011
    Inventors: Mohammad Luqman, Sherna Budhabhatti, Yongyu Wang, Seema Kantak, Ssucheng J. Hsu, Amer M. Mirza